DENYES NANCY 4
4 · aTYR PHARMA INC · Filed Feb 4, 2025
Insider Transaction Report
Form 4
aTYR PHARMA INCATYR
DENYES NANCY
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2025-02-03+2,687→ 27,454 total - Exercise/Conversion
Restricted Stock Unit
2025-02-03−2,687→ 2,687 total→ Common Stock (2,687 underlying) - Sale
Common Stock
2025-02-04$3.78/sh−899$3,398→ 26,555 total
Footnotes (5)
- [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]Includes 2,500 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan.
- [F4]Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
- [F5]The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.